Rabies srRNA Vaccine Demonstrates Robust Immune Response
Positive results have been announced from a phase 1 trial evaluating the safety, reactogenicity, and immunogenicity of the rabies vaccine candidate RBI-4000, Replicate Bioscience announced in a release.1 Data from the study, which was previously presented at the 2024 American Society of Gene and Cell Therapy Annual Meeting, was also published in Nature Communications.2 Rabies … Read more